CELG

ICYMI: Valuentum’s Improved Stock and ETF Web Pages

by

Valuentum has rolled out improved stock and ETF web pages on its website valuentum.com/. Now, subscribers can access key proprietary information on the stock and ETF web pages in addition to the customary stock and ETF reports. Dear reader, We have some exciting news that we can’t wait to share with you! At valuentum.com/, we have rolled out new stock and ETF pages that conveniently include a variety of our proprietary metrics from the Dividend Cushion ratio to the Economic Castle rating and beyond! There’s even mouseover functionality so you can learn about how we define the key metrics across our stock-selection and dividend growth methodologies. You’ll still have access to the stock and dividend reports on the landing pages, … Read more

Our Reports on Stocks in the Biotech Industry

by

Image Source: Celgene This listing has been discontinued. Please view the following links for our work on pharmaceutical stocks: Pharmaceuticals – Big: ABBV, ABT, AMGN, AZN, BMY, GSK, LLY, MRK, NVO, NVS, PFE, SNY Pharmaceuticals – Biotech/Generic: ALXN, AGN, BIIB, BMRN, CELG, GILD, MYL, REGN, TEVA, VRX, VRTX, ZTS Structure of the Biotechnology Industry Firms in the biotechnology industry face no certain future. Drug development is complex, difficult, and risky, and failure rates are high. Product development cycles are extended—approximately 10 to 15 years from discovery to market. A potential new medicine must undergo years of testing to establish safety/efficacy. Sales depend on reimbursement from third-party payers. Competition can be fierce when biosimilar products exist, though patents are material competitive advantages. We like the group on the … Read more

The “Luck” and “Randomness” of Index Funds

by

Please select the image below to download the document. Image shown, page 1 of 14. Tickerized for Valuentum’s coverage universe.

Updating Our Thoughts on Celgene

by

Image Source: Celgene Q4 2017 Earnings presentation Although the combination of disruptive new discoveries coupled with burgeoning demand thanks to the aging demographics of the world’s population sets the biotech space for a potential virtuous long-term cycle, we’re not too happy with with the recent developments at Celgene. Let’s dig in. By Alexander J. Poulos Pipeline Woes Continue The share price of Celgene (CELG) was accelerating heading into the Fall of 2017 as the strength of its existing oncology pipeline coupled with a few late-stage molecules augured well for a continued advance in the share price. As detailed in a recent piece aptly named “Celgene Implodes,” the costly discontinuation of Mongersen cast doubt on Celgene’s ability to hit its long-term … Read more

A Key Inflection Point for Gilead Sciences

by

We have closely followed events at Gilead Sciences for signs of an inflection point as we have long felt the market is myopically focused on the Hepatitis C franchise instead of cash flows. Our decision to add the idea to the simulated Dividend Growth Newsletter portfolio and the simulated Best Ideas Newsletter portfolio has played out very well as the share price remains locked in an uptrend. We are updating our thesis following the recent conference call. By Alexander J. Poulos Looking Past HCV Image Source: Gilead Sciences Lost in the cacophony of opinions on Gilead (GILD), we are amazed at the intense focus on the Hepatitis C franchise by the investment community. In our opinion, the HCV franchise remains … Read more

The Turnaround at Novartis Has Begun

by

Image Source: Novartis We believe Novartis is poised to accelerate from the patent cliff caused by the loss of protection of Gleevec, its former top-selling product. The company has a stellar dividend growth history, and the market is anticipating a turnaround once it anniversaries the patent cliff. By Alexander J. Poulos Novartis Innovative Medicines We will begin our analysis of Novartis (NVS) by breaking down the European pharma giant into three distinct divisions to gain a better perspective of the various moving parts that make up this very innovative company. The Innovative Medicines division houses the patent protected molecules that make up the bulk of the group’s revenues and an outsize portion of its profitability. The star of the show … Read more

The US Dollar, GDP Expansion, and Earnings

by

Investors wouldn’t think news flow is that robust given that stock market volatility in recent months has been practically nil, but news is coming in fast. Let’s check up on the performance of the US dollar, the rate of GDP growth as well as key companies reporting fourth-quarter earnings. Intel’s quarterly report was fantastic, for one!    By Kris Rosemann The US dollar (UUP, UDN, USDU) hit a three-year low against the euro, but US Treasury Secretary Steven Mnuchin suggests a weaker dollar may be good for the US, which is a change from traditional US policy, though he was sure to note that the government is not concerned about short-term fluctuations in the currency. Meanwhile, of course, the euro … Read more

Bioverativ’s Takeout, Visa’s Surge, and General Electric’s Pain

by

From Bioverativ’s takeout to Visa’s stock price surge to General Electric’s continued pain, there’s a lot going on in the stock market. Let’s cover some ground. By Kris Rosemann and Brian Nelson, CFA It’s hard to believe this but our best idea in the Best Ideas Newsletter portfolio, Visa (V), is now a $124+ per share stock. We know how to pick ‘em, would you say? We don’t get everything correct, of course, but if you’ve read anything on our website, we can only hope that you’ve witnessed Visa’s meteoric rise. The high end of our updated fair value estimate range for Visa is north of $130 per share. What a wild ride it has been, to say the least, … Read more

In the News: GE, O, EGO, CELG

by

There is a lot happening in the markets. Let’s have a look at some of the top news. By Kris Rosemann On January 16, General Electric (GE) announced a $6.2 billion write down related to its legacy reinsurance business, and market observers have taken to speculating about the fate of the industrial giant. Activist investor Nelson Peltz’s Trian Fund Management, which has watched the market value of its 2015 investment in GE dwindle, is reportedly pushing the conglomerate to explore strategic alternatives. Peltz and Trian have been in the middle of a number of battles for strategic power at the top of a number of US-based behemoths including the recently formed DowDuPont (DWDP) and Procter & Gamble (PG), and Trian … Read more

Video: Quants! You’re NOT Measuring VALUE and Nelson’s Theory of Universal Value

by

President of Investment Research Brian Nelson defines the concept of universal value and shows how quantitative statistical methods are inextricably linked to those of fundamental, financial, business-model related analysis. Value does not exist in respective process vacuums! Value is universal. Find out why. Running time: ~10 minutes.  Tickerized for Valuentum’s stock and ETF coverage universe. Transcript Hi this is Brian Nelson from Valuentum Securities, and this is the tenth edition of a series that I call “Off the Cuff,” where I get in front of the camera and I talk for ten minutes. This is what we have to talk about today. We have to talk about this concept: The Theory of Universal Value. Value does not exist in vacuums … Read more